Liquidia LQDA
NASDAQ LQDA
$68.68 +1.00 (+1.47%)
As of: Sep 9, 2026 · 2:36 PM EDT

Liquidia (LQDA) Income from Continuing Operations (2020 - 2026)

Liquidia (LQDA) posted Income from Continuing Operations of $74.7 million for Q2 2026, up 41.31% on a QoQ basis from $52.9 million in Q1 2026, and up 279.65% year-over-year from $19.7 million in Q2 2025.

Analysis

Liquidia (LQDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Liquidia has reported Income from Continuing Operations for 7 years, with the latest figure at $74.7 million in Q2 2026.

  • On a quarterly basis, Income from Continuing Operations rose 279.65% year-over-year to $74.7 million in Q2 2026; TTM through Jun 2026 was $138.6 million, a 192.71% increase from a year earlier, with the FY2025 full-year figure at -$68.9 million, up 46.28% from the prior year.
  • Income from Continuing Operations was $74.7 million for Q2 2026 at Liquidia, up from $52.9 million in the prior quarter.
  • The five-year high for Income from Continuing Operations was $74.7 million in Q2 2026, with the low at -$41.6 million in Q2 2025.
  • Average Income from Continuing Operations over 5 years is -$10.3 million, with a median of -$15.4 million recorded in 2022.
  • The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations sank 320.17% in 2023, then jumped 279.65% in 2026.
  • Over 5 years, Income from Continuing Operations stood at -$6.5 million in 2022, then tumbled by 320.17% to -$27.4 million in 2023, then slumped by 40.29% to -$38.5 million in 2024, then surged by 137.8% to $14.6 million in 2025, then soared by 413.21% to $74.7 million in 2026.
  • The last three Income from Continuing Operations figures came in at $74.7 million (Q2 2026), $52.9 million (Q1 2026), and $14.6 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 645.95 Bn 625.20 Bn 17.26 Bn 5.53 Bn
2 AbbVie 441.39 Bn 434.82 Bn 12.70 Bn 3.62 Bn
3 Merck 366.72 Bn 359.58 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 266.68 Bn 258.99 Bn 11.24 Bn 5.28 Bn
5 Pfizer 159.20 Bn 147.50 Bn 10.94 Bn -246.00 Mn
6 Sanofi 52.43 Bn 45.05 Bn 10.79 Bn 2.16 Bn
7 Revolution Medicines 44.08 Bn 44.08 Bn - -644.37 Mn
8 Incyte 25.50 Bn 20.96 Bn 1.57 Bn 585.61 Mn
9 United Therapeutics 21.54 Bn 18.88 Bn 683.80 Mn 333.00 Mn
10 Liquidia 6.10 Bn 5.81 Bn 160.92 Mn 74.70 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 74.70 Mn
Mar 31, 2026 52.86 Mn
Dec 31, 2025 14.56 Mn
Sep 30, 2025 -3.53 Mn
Jun 30, 2025 -41.58 Mn
Mar 31, 2025 -38.37 Mn
Dec 31, 2024 -38.51 Mn
Sep 30, 2024 -31.03 Mn
Jun 30, 2024 -28.67 Mn
Mar 31, 2024 -30.08 Mn
Dec 31, 2023 -27.45 Mn
Sep 30, 2023 -15.79 Mn
Jun 30, 2023 -23.52 Mn
Mar 31, 2023 -9.43 Mn
Dec 31, 2022 -6.53 Mn
Sep 30, 2022 -9.09 Mn
Jun 30, 2022 -9.45 Mn
Mar 31, 2022 -14.95 Mn
Dec 31, 2021 -11.56 Mn
Sep 30, 2021 -7.28 Mn